Floatz logo

Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide

Uterine Cancer

Explore 47 assets in Uterine Cancer →
Floatz Rating
CC47/100
Confidence
Indicative
v0.2
Sponsor
Genmab
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05579366CT.gov
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Uterine Cancer

AssetSponsorPhaseRating
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide (this asset)GenmabP1/2CC · 47
GALFERSunnybrook Health Sciences CentreP4BB
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Gynecologic Oncology AssociatesP4BB
MarcaineUniversity of California, IrvineP3B
NivolumabNational Cancer Institute (NCI)P2B
DurvalumabMary Crowley Medical Research CenterP2B
Gemogenovatucel-TGradalis, Inc.P2B
SirexatamabLeap Therapeutics, Inc.P2B
AtezolizumabGradalis, Inc.P2B

+42 more in the Uterine Cancer cohort

Other indications for Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide

IndicationSponsorPhaseRating
Ovarian Cancer—P3B · 62
Non-Small Cell Lung Carcinoma—P2CCC · 50
Ovarian Carcinoma—P1/2CCC · 48

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide in Uterine Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-240-alanine241-alanine-anti-human-folate-receptor-human-monoclonal-pro1184-1-chain-complex-with-human-monoclonal-pro1184-chain-dimer-214214226226232232235235-octakisthioether-with-n6-39-bis1-deoxy-d-glucitol-1-ylamino-1-oxo-4710131619222528313437-dodecaoxanonatriacont-1-yl-n2-6-3-mercapto-25-dioxo-1-pyrrolidinyl-1-oxohexyl-l-lysyl-l-valyl-n5-aminocarbonyl-n-4-1s9s-9-ethyl-5-fluoro-239101315-hexahydro-9-hydroxy-4-methyl-1013-dioxo-1h12h-benzodepyrano3467indolizino12-bquinolin-1-ylaminocarbonyloxymethylphenyl-l-ornithinamide-uterine-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →